Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor–independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease

Iris T. Chan,1 Jeffery L. Kutok,2 Ifor R. Williams,3 Sarah Cohen,1 Lauren Kelly,1 Hirokazu Shigematsu,4 Leisa Johnson,5 Koichi Akashi,4 David A. Tuveson,6 Tyler Jacks,7,8 and D. Gary Gilliland1,4,9

1Division of Hematology, Department of Medicine, and 2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA 3Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA 4Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts, USA 5Exelixis Inc., South San Francisco, California, USA 6Departments of Medicine and Cancer Biology, Abramson Family Cancer Research Institute, Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA 7Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA 8Howard Hughes Medical Institute, Center for Cancer Research, Cambridge, Massachusetts, USA 9Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA

Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic Kras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor–independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.


Received for publication November 5, 2003, and accepted in revised form January 7, 2004.

Address correspondence to: D. Gary Gilliland, Harvard Institutes of Medicine, 4 Blackfan Circle, Room 421, Boston, Massachusetts 02115, USA. Phone: (617) 525-5525; Fax: (617) 525-5530; E-mail: gillilan@hhg.med.harvard.edu.

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: acute myeloid leukemia (AML); GTPase-activating protein (GAP); guanine nucleotide exchange factor (GEF); phosphoinositide-3-kinase (PI3K); internal tandem duplication (ITD); neurofibromatosis 1 (NF1); juvenile myelomonocytic leukemia (JMML); long terminal repeat (LTR); mouse mammary tumor virus (MMTV); l-ox-stop-ox (LSL); polyinosinic-polycytidylic acid (pI-pC); allophycocyanin (APC); common myeloid progenitor (CMP); granulocyte-monoocyte progenitor (GMP); megakaryocyte-erythrocyte progenitor (MEP); stem cell factor (SCF); erythropoietin (EPO); pl-pC–treated LSL–K-ras G12D+/Mx1-Cre+ (KM+); LSL–K-ras G12D+/Mx1-Cre‘ (KM‘); LSL–K-ras G12D‘/Mx1-Cre’ not treated with pl-pC (KM‘); LSL–K-ras G12D‘ treated with pl-pC (KM‘); Mx1-Cre’ treated with pl-pC (M+); wild-type littermate treated with pl-pC (WT+); white blood cell (WBC); erythroid burst-forming unit (E-BFU); colony-forming unit (CFU); monocyte colony-forming unit (M-CFU); granulocyte-erythrocyte-megakaryocyte colony-forming unit (GEMM-CFU).

Introduction

Acute myeloid leukemia (AML) is characterized by an accumulation of immature myeloid precursors in the bone marrow and, in many cases, the peripheral blood. From analysis of recurrent chromosomal translocations in bone marrow samples from AML patients, it is clear that loss-of-function mutations in transcription factors critical for hematopoiesis are involved in leukemogenesis. These balanced reciprocal translocations often result in the expression of fusion proteins that act as dominant negative inhibitors of the normal transcription factors in hematopoietic development, such as the AML1-ETO product of the (8;21) translocation and the PML-RARα product of the (t(15;17) translocation. Loss-of-function point mutations in transcription factors involved in hematopoietic differentiation, such as C/EBPα and AML1, have also been identified in AML. Although these mutations involving hematopoietic transcription factors are necessary for AML pathogenesis, they are not sufficient (1–4). It is hypothesized that the AML phenotype
requires a combination of mutations in the hematopoietic progenitor cells, which contribute to impaired differentiation and an increased proliferation and/or survival advantage (5, 6). The *ras* proto-oncogenes are likely candidates for proteins in which gain-of-function mutations would confer the signals for enhanced cell proliferation and survival in AML pathogenesis.

The *ras* proteins are a family of guanine nucleotide-binding proteins involved in cell proliferation, differentiation, and survival (7–10). The ras signaling pathways are activated by a spectrum of hematopoietic cytokine receptors in response to ligand and therefore play important roles in the proliferation and enhanced survival of hematopoietic progenitors. Members of the ras family include K-ras, N-ras, and H-ras. They are expressed ubiquitously during development and must be post-translationally modified by farnesylation and/or geranylgeranylation for membrane localization and functional activity. The ras proteins cycle between an inactive GDP-bound state and an active GTP-bound state; this cycling is mediated by GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). In the GTP-bound state, ras activates the Raf/MAP kinase pathway, with subsequent activation of transcription factors and altered expression of genes promoting cell proliferation and differentiation. The ras proteins can also promote cell survival by activating the phosphoinositide-3-kinase (PI3K) pathway, with subsequent stimulation of AKT kinase and activation of multiple downstream effectors, post-translational modifications, subcellular localization, and proliferation in various human tumors (7, 11).

Oncogenic ras mutations are present in approximately 25–44% of AML patients and are among the most frequently detected genetic alterations in AML (12, 13). Activating *N-ras* mutations are detected in 20–25% of AML patients and *K-ras* mutations are seen in 10–15% of AML patients. These activating mutations most frequently involve single amino acid substitutions at *ras* codons 12, 13, or 61, which abrogate intrinsic ras GTPase activity and lead to constitutive ras activation.

In the absence of oncogenic ras mutations, ras may be activated through other mechanisms, such as the oncogenic activation of upstream tyrosine kinases seen in a significant proportion of AML cells, with consequent accumulation of ras-GTP. Examples of tyrosine kinase gain-of-function mutations in AML include *FLT3* activation loop point mutations, *FLT3* juxtamembrane region internal tandem duplications (ITDs) (14), *C-KIT* point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (16, 17) or TEL/ABL associated with t(9;12) (18, 19). Most of these tyrosine kinase mutations confer growth factor-independent growth to hematopoietic cell lines and cause a myeloproliferative disease in mouse models (17, 20, 21).

Dysregulation of ras-GAP is another mechanism of indirect ras activation in leukemic cells. Loss-of-function mutations in neurofibromatosis 1 (NF1), a ras-GAP protein, lead to accumulation of high levels of ras-GTP (22). Children with type 1 neurofibromatosis are predisposed to malignant myeloproliferative syndromes, which include monosomy 7 syndrome and juvenile myelomonocytic leukemia (JMML) (23). Mice heterozygous for NF1 deletion are prone to develop a myeloproliferative syndrome resembling human JMML (24). NF1-deficient mouse fetal liver cells demonstrate hypersensitivity to GM-CSF stimulation and elevated levels of ras-GTP (25, 26) and confer a JMML-like myeloproliferative disease upon transplantation (25).

To date, activating *ras* mutations have been studied in various cell culture, bone marrow transplantation, and transgenic mice model systems expressing *ras* from exogenous promoters. A variety of phenotypes has been reported. CD34+ stem cells transduced with amphotrophic retrovirus expressing oncogenic N-ras had impaired erythropoietin-induced erythroid differentiation at the late erythroblast stage, reminiscent of a myelodysplastic phenotype (27, 28), and impaired G-CSF- and GM-CSF-induced granulocytic differentiation at the blast/promyelocyte stage (29). In a transplant model using bone marrow cells retrovirally transduced with oncogenic *N-ras*, recipient mice developed myeloproliferative disorders with long latency (107–385 days) and incomplete penetrance, suggesting that secondary mutations were necessary for the phenotype (30). Mice transplanted with bone marrow cells retrovirally transduced with viral *H-ras* developed peripheral myeloid leukocytosis, as well as frequent pre–T thymic lymphomas and/or pre–B cell lymphoblastic leukemia/lymphomas (31). Mice transplanted with bone marrow cells expressing oncogenic *H-ras* from the Moloney MuLV long terminal repeat (LTR) promoter often developed thymic lymphomas (32). Transgenic mice expressing activated *N-ras* from the mouse mammary tumor virus (MMTV) LTR developed lymphoblastic T cell and B cell lymphomas and poorly differentiated mammary carcinomas (33). Transgenic mice expressing viral *H-ras* from the MMTV promoter/enhancer developed B cell lymphoblastic lymphomas at low frequency (34).

As is evident from the studies described above, a consistent phenotype from oncogenic ras expression in hematopoietic cells has not been established, in part because different exogenous promoters were used to express various oncogenic ras isoforms at supraphysiological levels and often in nonphysiological tissues. The variety of malignancies that developed likely reflected the tissue specificities of the promoters used rather than the specific transforming capabilities of oncogenic ras. The phenotypes generated from overexpression of genes from exogenous reporters may be very different from the phenotypes that arise when genes are expressed from their endogenous reporters. The critical role of gene dosage in
cancer is supported by data indicating that haploinsufficiency may contribute to oncogenesis (35, 36).

In this study, a conditional expression strategy was used to characterize the biological consequences of expressing oncogenic K-ras from its endogenous promoter in hematopoietic cells. Expression of oncogenic ras in the mice induced a myeloproliferative syndrome with short latency and high penetrance, similar to that observed with leukemia-associated activated receptor tyrosine kinases, and conferred growth factor-independent colony formation of primary bone marrow cells.

**Methods**

**Mouse strains.** Lox-stop-lox (LSL)–K-ras G12D mice (on mixed 129Sv/Jae and C57BL/6 backgrounds) were crossed to Mx1–Cre transgenic mice (37) (on a BALB/c background) to obtain double-transgenic LSL–K-ras G12D+/Mx1-Cre+ mice on a mixture of 129Sv/Jae, C57BL/6, and BALB/c genetic backgrounds. For induction of Cre expression, 4- to 7-week-old mice were injected intraperitoneally with 250 μg of polyinosinic-polycytidyllic acid (pI-pC; Sigma-Aldrich, St. Louis, Missouri, USA) every other day for three doses. All mice were housed in microisolator cages, were monitored daily for evidence of disease, and were sacrificed when moribund. All experiments were conducted with the ethical approval of the Harvard Medical Area Standing Committee on Animals.

**Molecular and biochemical analysis.** LSL–K-ras G12D mice were genotyped by PCR amplification of genomic DNA obtained from tail tissue to detect the 500-bp lox–K-ras and 315-bp excised products. For verification of Cre-mediated recombination, DNA from mouse bone marrow, spleen, and liver containing media using MethoCult GF M3231 media from which SCF, IL3, IL6, and EPO were absent. For primary methylcellulose cultures, 4 × 10^6 to 1 × 10^7 cells were seeded in duplicate and harvested after 10 days. Cytospin preparations of individual colonies were stained with Wright-Giemsa solutions. Serial replating assays were performed as previously described (44) in two independent experiments with 10^4 cells replated in duplicate for each round of replating and colony counts performed on day 7.

**Murine bone marrow transplantation.** Bone marrow cells were harvested from the femurs and tibias of p1-pC-treated LSL–K-ras G12D+/Mx1-Cre+ (KM+) mice. After red blood cell lysis, cells were washed in PBS, resuspended in Hank’s balanced salt solution (Invitrogen Life Technologies, Carlsbad, California, USA), and injected (10^6 cells/0.5 ml) into the lateral tail veins of sublethally irradiated (650 cGy) wild-type littermates. Mice were housed in microisolator cages and were provided with autoclaved chow and acidified water.

**Results**

**Generation of mice expressing endogenous levels of oncogenic K-ras in the hematopoietic system.** We studied LSL–K-ras G12D mice harboring a conditional oncogenic K-ras allele
targeted to the endogenous K-ras locus by homologous recombination. The conditional allele contains a cassette with a transcriptional termination stop codon flanked by loxP sites (LSL cassette) located upstream of a mutation of glycine to aspartic acid in codon 12 (38) (Figure 1a). The stop cassette prevents potential deleterious consequences of expression of the oncogenic K-ras allele during development. However, Cre recombinase–mediated excision of the stop cassette in adult animals allows expression of oncogenic K-ras from the endogenous K-ras promoter sequences, thus preserving temporal, lineage-appropriate, and quantitative transcriptional regulation. For expression of oncogenic K-ras in the hematopoietic system, LSL–K-ras G12D mice were crossed to Mx1-Cre transgenic mice that express Cre from the IFN-α/β-inducible Mx1 promoter (Figure 1b) (37). Cre expression from the Mx1 promoter is induced in vivo by treating mice with IFN-α/β or pl-pC, a synthetic double-stranded RNA that induces expression of endogenous IFN. In this way, Cre expression, subsequent excision of the stop cassette, and expression of oncogenic K-ras will occur in cells expressing the IFN receptor, including hematopoietic cells.

**Oncogenic K-ras expression in hematopoietic cells results in a myeloproliferative disorder.** All pl-pC–treated LSL–K-ras G12D+/Mx1-Cre+ (KM+) mice developed a lethal hematopoietic disease with a median survival of 35 days ($P < 0.0001$ compared with negative controls by log rank test; range, 16–67 days) (Figure 1c). Of interest, all LSL–K-ras G12D+/Mx1-Cre– mice that were not treated with pl-pC (KM– mice) also developed a similar hematopoietic disease with a longer median survival of 58 days ($P = 0.0039$, KM+ vs. KM– mice, by log rank test). The negative controls, single-transgenic LSL–K-ras G12D+ mice, Mx1-Cre+ mice, or wild-type littermate mice treated with pl-pC (K+, M+, or WT+ mice, respectively), showed no evidence of disease. The predominant phenotype identified in all KM+ mice examined was a myeloproliferative disorder characterized by leukocytosis, splenomegaly, and myeloid hyperplasia in the bone marrow. White blood cell (WBC) counts ranged between $18 \times 10^9/\mu l$ and $99 \times 10^9/\mu l$ with a median WBC count of $36 \times 10^9/\mu l$ (Table 1). KM– mice also developed leukocytosis with median WBC counts of $35 \times 10^9/\mu l$. In the vast majority of cases, leukocytosis in KM+ mice was due to an increase in the granulocyte population. For example, in KM+ mice, neutrophils accounted for 15–65% of WBCs (median, 42%; $n = 22$), compared with K+, M+, and WT+ mice, in which neutrophils were 12–43% of WBCs (median, 19%; $n = 24$; $P < 0.001$ by Mann-Whitney test). There were no significant differences in the absolute numbers of other WBC subsets, although there was a slight increase in the percentage of atypical lymphocytes. KM+ mice were anemic, with a mean hematocrit of 27% (range, 11–48%), compared with a normal mean hematocrit of 45% in the K+, M+, and WT+ controls ($P < 0.001$ by Mann-Whitney test). There were no appreciable differences in the platelet counts between experimental and control mice.

KM+ mice were emaciated, with ruffled fur and moderate-to-severe palpable splenomegaly. Spleen weights ranged between 205 and 2,300 mg, compared with normal-sized spleens (67–133 mg) in K+, M+, and WT+ negative control mice ($P < 0.001$; Table 1 and Figure 1d). Hematoxylin and eosin–stained sections of spleen...
showed marked extramedullary hematopoiesis with effacement of splenic architecture and expansion of the red pulp compartment by varying degrees of granulocytic, monocytic, erythroid, and megakaryocytic lineage cells (Figure 2). Eleven of sixteen cases examined demonstrated a predominantly granulocytic/monocytic proliferation within the spleen and a hypercellular bone marrow revealing myeloid (predominantly granulocytic) hyperplasia (Figure 2). In the remaining five of sixteen cases examined, marked extramedullary hematopoiesis in the spleen was also observed; however, this represented a striking erythroid expansion with fewer numbers of granulocytic and monocytic forms. A more subtle expansion of myeloid elements was seen in the bone marrow of these mice. In all cases examined, the liver showed significant perivascular and periportal infiltration by populations of myeloid and erythroid cells identical to those seen in the spleen (Figure 2). The overall hematopoietic phenotype was similar to the myeloproliferative diseases induced in murine bone marrow transplant assays by tyrosine kinase fusions such as BCR-ABL, TEL-PDGFRβ, TEL-TRKC, and TEL-JAK2 (17, 41, 45, 46). Interestingly, other pathological findings observed with high frequency but incomplete penetrance in KM+ mice were squamous papillomas involving the anal and vulvo-vaginal skin (12 of 19), ear (8 of 22), esophageal mucosa (14 of 17), and oral mucosa (8 of 25) (Figure 3). In addition, multiple nodules were observed in the lungs of KM+ mice (10 of 17), consisting of proliferating type II pneumocytes that stained positive for keratin (data not shown). These findings are consistent with the adenomas previously described in the lungs of LSL–K-ras G12D mice treated with intranasal instillation of adenovirus-expressing Cre (38). Finally, thymic T cell lymphoblastic lymphomas (7 of 25) and nodal lymphoid hyperplasia distinct from sinusoidal infiltrates of myeloid elements (6 of 17) were also noted.

In KM– mice, extramedullary hematopoiesis in the spleen and liver was also evident. In six cases examined, one mouse demonstrated a marked myeloproliferative disease; four had mild, predominantly myeloid extramedullary hematopoiesis in the spleen and liver with mild myeloid (predominantly granulocytic) hyperplasia in the marrow; and one mouse had no hematopoietic abnormalities. In a subset of KM– mice, pulmonary adenomas (five of six), thymic lymphomas (two of six), oral squamous papillomas (two of six), and ear squamous papillomas (two of six) were also observed. No vulvo-vaginal, anal or esophageal squamous papillomas were observed in KM– mice (n = 6).

Flow cytometric analysis of spleen cells (Figure 4a) from KM+ mice further confirmed the myeloproliferative phenotype. In the spleen, 17–20% of cells were positive for the myeloid markers Gr-1 (Ly 6-G) and Mac-1, indicative of mature neutrophils, compared with 5–6% for K+, M+, and WT+ negative control mice. In untreated KM– mice, Gr-1+/Mac-1+ cells represented 12% of spleen cells. The increased percentage of myeloid cells was associated with a concomitant decrease in the percentages of CD4 and CD8+ T cells. The overall hematopoietic phenotype was similar to the myeloproliferative diseases induced in murine bone marrow transplant assays by tyrosine kinase fusions such as BCR-ABL, TEL-PDGFRβ, TEL-TRKC, and TEL-JAK2 (17, 41, 45, 46). Interestingly, other pathological findings observed with high frequency but incomplete penetrance in KM+ mice were squamous papillomas involving the anal and vulvo-vaginal skin (12 of 19), ear (8 of 22), esophageal mucosa (14 of 17), and oral mucosa (8 of 25) (Figure 3). In addition, multiple nodules were observed in the lungs of KM+ mice (10 of 17), consisting of proliferating type II pneumocytes that stained positive for keratin (data not shown). These findings are consistent with the adenomas previously described in the lungs of LSL–K-ras G12D mice treated with intranasal instillation of adenovirus-expressing Cre (38). Finally, thymic T cell lymphoblastic lymphomas (7 of 25) and nodal lymphoid hyperplasia distinct from sinusoidal infiltrates of myeloid elements (6 of 17) were also noted.

In KM– mice, extramedullary hematopoiesis in the spleen and liver was also evident. In six cases examined, one mouse demonstrated a marked myeloproliferative disease; four had mild, predominantly myeloid extramedullary hematopoiesis in the spleen and liver with mild myeloid (predominantly granulocytic) hyperplasia in the marrow; and one mouse had no hematopoietic abnormalities. In a subset of KM– mice, pulmonary adenomas (five of six), thymic lymphomas (two of six), oral squamous papillomas (two of six), and ear squamous papillomas (two of six) were also observed. No vulvo-vaginal, anal or esophageal squamous papillomas were observed in KM– mice (n = 6).

Flow cytometric analysis of spleen cells (Figure 4a) from KM+ mice further confirmed the myeloproliferative phenotype. In the spleen, 17–20% of cells were positive for the myeloid markers Gr-1 (Ly 6-G) and Mac-1, indicative of mature neutrophils, compared with 5–6% for K+, M+, and WT+ negative control mice. In untreated KM– mice, Gr-1+/Mac-1+ cells represented 12% of spleen cells. The increased percentage of myeloid cells was associated with a concomitant decrease in the percentages of CD4 and

<table>
<thead>
<tr>
<th>Genotype</th>
<th>pI-pC</th>
<th>WBC × 10³ per µl (median)</th>
<th>Hct % (median)</th>
<th>Platelets per µl (median)</th>
<th>Spleen weight (median)</th>
<th>Liver weight (median)</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>KM+</td>
<td>+</td>
<td>18–99 (36)</td>
<td>11–47 (26)</td>
<td>434–2,081 (1,194)</td>
<td>205–2,300 (677)</td>
<td>882–2,290 (1,703)</td>
<td>MPD</td>
</tr>
<tr>
<td></td>
<td>n = 22</td>
<td></td>
<td>n = 22</td>
<td></td>
<td>n = 25</td>
<td>n = 25</td>
<td></td>
</tr>
<tr>
<td>KM–</td>
<td>–</td>
<td>8–83 (35)</td>
<td>34–53 (41)</td>
<td>156–885 (583)</td>
<td>70–1,271 (540)</td>
<td>704–2,777 (1491)</td>
<td>MPD</td>
</tr>
<tr>
<td></td>
<td>n = 6</td>
<td></td>
<td>n = 6</td>
<td></td>
<td>n = 8</td>
<td>n = 8</td>
<td></td>
</tr>
<tr>
<td>K+</td>
<td>+</td>
<td>2.9–7.5 (4.8)</td>
<td>43–52 (46)</td>
<td>719–1,412 (1,020)</td>
<td>70–133 (107)</td>
<td>900–1,930 (1,404)</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>n = 9</td>
<td></td>
<td>n = 9</td>
<td></td>
<td>n = 11</td>
<td>n = 11</td>
<td></td>
</tr>
<tr>
<td>M+</td>
<td>+</td>
<td>2.6–5 (4.6)</td>
<td>36–47 (43)</td>
<td>518–1,218 (904)</td>
<td>80–124 (104)</td>
<td>940–2,000 (1,292)</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>n = 6</td>
<td></td>
<td>n = 6</td>
<td></td>
<td>n = 8</td>
<td>n = 8</td>
<td></td>
</tr>
<tr>
<td>WT+</td>
<td>+</td>
<td>4.3–8.4 (6.3)</td>
<td>43–50 (47)</td>
<td>551–1,336 (1,074)</td>
<td>67–120 (90)</td>
<td>1,069–1,756 (1,437)</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>n = 9</td>
<td></td>
<td>n = 9</td>
<td></td>
<td>n = 10</td>
<td>n = 10</td>
<td></td>
</tr>
</tbody>
</table>

Spleen and liver weights are presented in milligrams. MPD, myeloproliferative disease.

**Table 1**

**Phenotype of KM+ and KM– mice**

**Figure 2**

Mice expressing oncogenic K-ras develop a myeloproliferative disease. Representative histopathology (original magnifications in parentheses) from peripheral blood (×100), bone marrow (×100), spleen (×40), and liver (×20), showing expansion of predominantly mature myeloid elements, without an increase in immature/blast forms.
CD8 single-positive T cells and CD19+ B cells. Flow cytometric analysis of KM+ bone marrow cells also showed evidence of myelomonocytic expansion, with 77–81% Gr-1+/Mac-1+ cells, compared with 64–70% Gr-1+/Mac-1+ cells in negative control K+, M+, and WT+ mice (Figure 4b). Erythroid lineage Ter-119+ cells were present in normal percentages, except in anemic KM+ animals, which had an increased percentage of Ter-119+ cells (Figure 4a).

Further analysis of K+, M+, and KM+ bone marrow demonstrated no significant differences in the relative percentages of myeloid progenitor populations (Figure 5), composed of IL-7R\(\alpha\)–Lin–c-Kit+Sca-1– cells (43), or in the relative percentages of CMP, GMP, and MEP subpopulations (Figure 5). This result must be interpreted with caution, as it is not known whether K-ras is normally expressed in the myeloid progenitor compartment. In KM+ spleen, the relative percentages of CMP, GMP, and MEP populations increased, reflecting increased extramedullary hematopoiesis.

**Oncogenic K-ras expression.** Cre-mediated excision of the stop cassette upstream of the oncogenic K-ras allele was demonstrated via PCR of genomic DNA from various tissues (Figure 6a). Only DNA from diseased KM+ and KM– tissues yielded a PCR product 30 bp larger than the wild-type allele, corresponding to excision of the transcriptional stop cassette and the presence of the oncogenic K\(\text{ras}\) allele containing a single loxP site. Expression of oncogenic K-ras protein was demonstrated by Western blot analysis in diseased KM+ and KM– tissues but not in tissues from K+, M+, or WT+ negative control mice (Figure 6b).

**Colony-forming unit activity.** Bone marrow cells from KM+, K+, and M+ mice were plated in methylcellulose cultures in the presence or absence of growth factors (SCF, IL-3, IL-6, and EPO). All formed colonies in the presence of growth factors (Figure 7a). However, only bone marrow cells from KM+ mice readily formed colonies in a growth factor–independent manner. These colonies were smaller in size and less differentiated than colonies that grew in the presence of growth factors. In addition, colonies derived from KM+ bone marrow did not exhibit any enhanced serial replating activity.

---

**Figure 3**
Mice expressing oncogenic K-ras develop esophageal squamous papillomas and lung adenomas. Shown are normal gastroesophageal junction from M+ mouse (×10) and esophageal squamous papilloma (×5), ear squamous papilloma (×2), and lung adenomas (×5; inset, ×40) from KM+ mice. Original magnifications in parentheses.

**Figure 4**
Flow cytometric analysis of spleen and bone marrow cells. (a) Spleen cells from KM+ (n = 4), KM– (n = 2), and negative control WT+, K+, and M+ mice (n = 2 each) were stained with a combination of antibodies to Gr-1, Mac-1, CD4, CD45, Ter-119, Thy-1, and CD19. Dot plots were gated for live cells based on forward and side scatter profiles. Representative data are shown. (b) Bone marrow cells from KM+ (n = 4) and negative control mice (n = 2 each) were stained with a combination of antibodies to Gr-1, Mac-1, c-Kit, CD4, CD8, Ter-119, and CD45. Dot plots were gated for live cells based on forward and side scatter profiles. Representative data are shown. The percentages of cells in quadrants of interest are indicated.
activity (Figure 7b). Genomic DNA prepared from individual methylcellulose culture colonies was assayed for the presence of the activated \( K-ras \) allele. Only DNA from individual KM+ colonies yielded a PCR product corresponding to excision of the stop cassette and activation of the oncogenic \( K-ras \) allele. The activated \( K-ras \) allele was detected in KM+ colonies that grew in the presence or absence of growth factors. In individual methylcellulose colonies, the Cre excision efficiency was 100% in KM+ bone marrow–derived cells (\( n = 42; \) Figure 7 and data not shown). The phenotype of individual colonies was determined by microscopic visualization of Wright-Giemsa–stained cytospin preparations (Figure 7, d and e). In duplicate experiments, no erythroid burst-forming unit (E-BFU) colonies were observed in K+, M+, or KM+ methylcellulose cultures harvested on day 10. Subsequent experiments with KM+ and negative control bone marrow cells demonstrated E-BFU colonies in comparable numbers when cultures were harvested on day 7 (data not shown). Colonies derived from K+, M+, or KM+ bone marrow cells grown in the presence of growth factors formed granulocyte-monocyte colony-forming unit (GM-CFU) and granulocyte-erythrocyte-monocyte-megakaryocyte colony-forming unit (GEMM-CFU) colonies with similar efficiencies. In contrast, colonies derived from KM+ bone marrow cells in the absence of growth factors were predominantly monocyte colony-forming units (M-CFUs), composed of >95% macrophages. Similar results demonstrating growth factor–independent colony formation of predominantly M-CFUs were observed in methylcellulose cultures of oncogenic K-ras bone marrow cells in a model using LSL–K-ras \( G12D^-/Lys-Cre^+ \) mice in which the oncogenic \( K-ras \) allele was activated in cells expressing Cre driven by the lysozyme M promoter (I.T. Chan and D.G. Gilliland, unpublished observations).

Transplantability. Bone marrow cells (10^6) from diseased KM+ mice were transplanted into semilethally irradiated wild-type littermate secondary recipients. To date, all transplant recipients remain healthy and disease-free after 120 days (data not shown), indicating that the myeloproliferative disease was not transplantable into secondary recipients.

Discussion

Expression of oncogenic \( K-ras \) from its endogenous promoter in the hematopoietic system is sufficient to induce a myeloproliferative syndrome with relatively
short latency. The myeloproliferative syndrome induced by oncogenic K-ras is similar to the myeloproliferative syndromes induced by activated receptor tyrosine kinases (e.g., FLT3-ITD, BCR-ABL, TEL-PDGFRβ, and TEL-JAK2). This finding is somewhat surprising, as receptor tyrosine kinases activate multiple signaling pathways in addition to ras, such as the PI3K and JAK/STAT pathways. Indeed, disruption of PI3K/AKT or STAT signal transduction by pharmacologic or genetic strategies can abrogate transformation properties and diseases induced by receptor tyrosine kinases (46–52). As oncogenic K-ras is expressed from its endogenous promoter in this study, we may infer from these observations that oncogenic K-ras is at least as potent an allele as constitutively activated receptor tyrosine kinases that activate several signaling pathways including ras/MAP kinase. The inference is supported by epidemiological observations that activating mutations in FLT3 and ras are commonly found in AML, but rarely coexist in the same patient. The myeloproliferative disease observed in KM+ mice appears similar to the JMML-like disease in mice transplanted with NF1–/– fetal liver cells (25) and the myeloproliferative disease observed with long latency and incomplete penetrance in the oncogenic N-ras bone marrow transplant model (30).

It is interesting that the predominant phenotype induced by oncogenic K-ras is a granulocyte-rich myeloproliferative disease, as Mx1 promoter activation appears to occur very early in hematopoietic develop-
ment. In a model of conditional AML1-ETO expression utilizing Mx1-Cre–mediated recombination, persistent expression of AML1-ETO occurs throughout the life of the mice, suggesting that Cre-mediated deletion of the stop cassette occurs in long-term repopulating hematopoietic progenitors (1). Mx1-Cre–induced expression of oncogenic K-ras in hematopoietic stem cells might be expected to engender not only myeloid proliferation but also megakaryocyte hyperplasia or lymphoproliferative disease. Still, neutrophil lineage cells may be more sensitive to activation of the ras/MAP kinase pathway. This hypothesis is supported by the observation that loss of NFI function in the germine also favors development of neutrophil lineage disease. Oncogenic K-ras may contribute to lymphoid diseases, as there was evidence of lymphoid hyperplasia (enlarged lymph nodes) and lymphoid malignancy (lymphoblastic lymphoma) in the KM+ and KM– mice. Mutations in ras have not been identified in patients with myeloproliferative diseases such as polycythemia vera and essential thrombocythemia (53–56). It is uncertain whether the erythroid hyperplasia seen in some KM+ mice is the result of secondary erythroid hyperplasia in response to anemia or oncogenic K-ras is capable of directly inducing erythropoiesis, albeit ineffectively. Excision of the stop cassette in erythroid, megakaryocytic, or T- and B-lymphoid–specific Cre strains will directly address the question of whether oncogenic K-ras is capable of inducing proliferative diseases in these lineages.

Earlier cell culture, transgenic and bone marrow transplant models of H- or N-ras overexpression using heterologous promoters in the hematopoietic system yielded various phenotypes, including myeloproliferative diseases/leukemias with long latency and incomplete penetrance (30), impaired erythroid and myeloid differentiation suggestive of myelodysplasia (27–29), and pre–T thymic lymphomas and/or pre–B cell lymphoblastic leukemias/lymphomas (31–34). The variety of malignancies arising in these models likely reflects the tissue specificities and expression levels of the promoters used rather than the specific transforming properties of oncogenic ras. In KM+ mice, one copy of the oncogenic K-ras allele is expressed from its endogenous promoter, which more accurately recapitulates the genotype of human AML.

KM– mice, which were not induced with pl-pC, also developed a myeloproliferative syndrome, albeit of intermediate severity, with lower WBC counts, mild to moderate splenomegaly, and longer latency than that of KM+ mice. This is most likely due to endogenous IFN expression of sufficient levels to induce the Mx1-Cre transgene and activate oncogenic K-ras expression. Indeed, untreated AML1-ETO/KM1-Cre+ mice demonstrate low levels of recombination in the bone marrow, ranging from 9% to 20% when monitored for 24 weeks (1). Similarly, untreated DNA polymerase β/KM1-Cre+ mice demonstrate background recombination levels as high as 10% in the spleen, also attributed to endogenous IFN production (37). It is likely that endogenous IFNs in untreated KM– mice activate expression of oncogenic K-ras in a small percentage of long-term repopulating hematopoietic progenitors. Oncogenic K-ras expression confers a proliferative advantage to these progenitors; eventually, their expansion yields the myeloproliferative phenotype, although with slightly delayed latency.

KM+ and KM– mice demonstrate additional histopathological findings with incomplete penetrance. Oncogenic ras mutations are detected in squamous papillomas and squamous cell carcinomas (57) and are important for initiation and progression of these lesions. Transgenic mice expressing v-H-ras from the ζ-globin promoter develop skin papillomas with high frequency in response to trauma or chemical carcinogens (58). In rare instances, activating ras mutations have been reported in lymphomas (59). The pattern of premalignant tumors observed in KM+ and KM– mice likely reflects the patterns of IFN-induced Mx1-Cre and subsequent oncogenic K-ras expression. In studies of Mx1-Cre–mediated recombination of a floxed DNA polymerase β gene, pl-pC treatment yielded high recombination efficiencies in hematopoietic tissues (liver, 100%; spleen, 94%; and thymus, 40%) and lower levels in nonhematopoietic tissues such as heart, kidney, lung, and duodenum (37). Experiments with mice doubly transgenic for the β-galactosidase reporter ROSA26tm1Sor and Mx1-Cre demonstrate Cre expression in liver, spleen, pulmonary endothelium, kidney, and gastric epithelium (60). Papillomas and thymic lymphomas have been previously observed in 30% of adenovirus-Cre–treated oncogenic K-ras mice (40). Additional mutations are likely required to form these premalignant lesions; the low frequency of these lesions observed in KM+ and KM– mice may reflect a stochastic requirement for acquisition of additional oncogenic mutations, as well as the varying levels of IFN in those specific tissues. It is unlikely that development of these lesions depends on the penetrance of pl-pC into the various tissues, as a subset of untreated KM– mice also develop the same pattern of papillomas, lung nodules, and thymic lymphomas. KM+ mice may be a useful model system for studying carcinogenesis in squamous cell cancers with particular utility in modeling cancer prevention strategies.

Previous studies of ras overexpression in primary cells demonstrated growth arrest and apoptosis (61–63). More recently, it has been hypothesized that thresholds of ras activity exist, such that low, intermittent signaling contributes to cellular homeostasis; modest increases promote proliferation without triggering protective tumor suppressor or growth arrest pathways; and high, sustained levels induce growth arrest and senescence (7). Consistent with this hypothesis, our results with primary bone marrow methylcellulose cultures show that oncogenic ras expression from its endogenous promoter promotes a proliferative signal that bypasses the requirement for signals from growth factors and allows colony formation independent of growth factors.
Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, S2). The oncogenic K-ras–expressing colonies do not have enhanced immortalization/self-renewal properties, as assessed in serial replating assays. In distinct contrast, primary mouse embryonic fibroblasts expressing endogenous levels of oncogenic K-ras bypass proliferative senescence and are immortalized (64). These differences are consistent with the hypothesis that the effects of oncogenic K-ras are dependent on cellular context (64). Additional mutations may be required to induce an immortalization or self-renewal phenotype in the hematopoietic cells.

Like activated receptor tyrosine kinases in myeloproliferative diseases, oncogenic ras is implicated in AML pathogenesis by virtue of its presence in a high percentage of AML samples. Still, oncogenic ras is not sufficient to induce AML, as oncogenic K-ras induced myeloproliferative disease is not transplantable into secondary recipients. Additional mutations are likely required. We favor a model in which the AML phenotype requires at least two cooperating mutations: one that promotes proliferation and enhanced survival (such as oncogenic ras or an activated receptor tyrosine kinase), and one associated with impaired differentiation and an immortalization phenotype (such as a loss-of-function mutation in a hematopoietic transcription factor, as has been reported for AML1-ETO; ref 1). It will be important to test this hypothesis by analyzing oncogenic K-ras mice in the context of additional mutations associated with impaired hematopoietic differentiation, such as AML1-ETO (1) or PML-RARα (2). Ultimately, these oncogenic K-ras/Mx1-Cre models will be useful for testing novel therapeutic agents, such as farnesyltransferase and geranylgeranyltransferase inhibitors, which target ras (65, 66), and other agents such as ERK inhibitors, which target the ras/MAP kinase pathway.

Oncogenic ras mutations have been detected in other hematologic malignancies such as multiple myeloma, myelodysplasia, chronic myelomonocytic leukemia, and acute lymphoblastic leukemia (12, 13). As noted above, crosses of LSL–K-ras G12D mice with other transgenic mice strains expressing Cre from hematopoietic-specific promoters, such as Lys-Cre, Vav-Cre, CD19-Cre, and Lck-Cre, may yield new insights to the contributions of oncogenic K-ras in myeloproliferative and lymphoproliferative diseases as well as AML.

Many downstream effectors are activated by ras, including the Raf/MEK/ERK pathway, the PI3K/ AKT pathway, and RalGEFs. It would be interesting to determine which of these pathways is required for oncogenic ras-mediated myeloproliferative disease. Selective mutation of the ras effector domain (residues 32–40) can disrupt binding and activation of individual effector pathways (67–70). Generation of additional mice harboring various conditionally oncogenic K-ras mutations activating only single effector pathways for subsequent crosses to Mx1-Cre mice will yield additional insights into the pathogenesis of ras-induced myeloproliferative diseases with implications for the development of molecularly targeted therapies.

Finally, data are gradually accumulating regarding differences between H-, N-, and K-ras. The phenotypes of H-ras, N-ras, and K-ras knockout mice indicate clear distinctions in function and/or expression between family members. H-ras and N-ras knockout mice are viable with no overt abnormalities (71, 72). In contrast, K-ras knockout mice die at embryonic day 12.5 from severe anemia secondary to defects in the fetal liver microenvironment (39, 73). In addition, ras isoforms differ with respect to post-translational modifications, subcellular localization, and transformation properties (7, 11). Furthermore, N-ras mutations occur nearly exclusively in hematologic malignancies, whereas oncogenic K-ras and H-ras mutations are detected more often in solid tumors. In this Mx1-Cre mouse model, it is possible that the phenotypes from oncogenic N- or H-ras expression may be different from that of oncogenic K-ras. It will be informative to study the analogous conditional oncogenic H-ras and oncogenic N-ras alleles to understand differences in these ras isoforms and their contributions to oncogenesis.

Acknowledgments

We gratefully acknowledge administrative assistance from Alexis Bywater, and helpful discussions with members of the Gilliland lab. We also thank Benjamin Braun, Kevin Shannon, and Benjamin Neel for careful review of the manuscript. This work was supported in part by NIH grants DK51564 and CA66996 (D.G. Gilliland), a National Research Service Award for Postdoctoral Trainees (I.T. Chan) and the Leukemia and Lymphoma Society (D.G. Gilliland and I.T. Chan). D.G. Gilliland is an Associate Investigator of the Howard Hughes Medical Institute.


